Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026

Vaxcyte, Inc.

Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.
Cash, equivalents and investments $2.5B as of June 30, 2026, up from $2.44B at year-end 2025.
VAX-31 adult Phase 3 OPUS-1 noninferiority trial fully enrolled; topline data due Q4 2026.
VAX-31 infant Phase 2 dose-finding study data expected by end of H1 2027.
Phase 1 study of VAX-A1 (Group A Strep) initiated; topline data expected H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.